Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| 20 DMA Support | Bullish | 2.43% | |
| Pocket Pivot | Bullish Swing Setup | 2.43% | |
| Gapped Down | Weakness | 2.43% | |
| Crossed Above 20 DMA | Bullish | 2.59% | |
| Slingshot Bearish | Bearish Swing Setup | 5.15% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 11 hours ago |
| Rose Above 50 DMA | about 11 hours ago |
| Up 5% | about 11 hours ago |
| Up 1 ATR | about 11 hours ago |
| Up 3% | about 11 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.56 |
| 52 Week Low | 23.14 |
| Average Volume | 502,765 |
| 200-Day Moving Average | 28.09 |
| 50-Day Moving Average | 26.27 |
| 20-Day Moving Average | 24.82 |
| 10-Day Moving Average | 24.48 |
| Average True Range | 1.04 |
| RSI (14) | 55.36 |
| ADX | 20.56 |
| +DI | 21.56 |
| -DI | 19.35 |
| Chandelier Exit (Long, 3 ATRs) | 23.50 |
| Chandelier Exit (Short, 3 ATRs) | 26.25 |
| Upper Bollinger Bands | 26.53 |
| Lower Bollinger Band | 23.11 |
| Percent B (%b) | 0.76 |
| BandWidth | 13.77 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.56 |
| MACD Histogram | 0.2373 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.29 | ||||
| Resistance 3 (R3) | 28.23 | 27.31 | 27.86 | ||
| Resistance 2 (R2) | 27.31 | 26.66 | 27.34 | 27.71 | |
| Resistance 1 (R1) | 26.52 | 26.26 | 26.92 | 26.58 | 27.57 |
| Pivot Point | 25.60 | 25.60 | 25.80 | 25.63 | 25.60 |
| Support 1 (S1) | 24.81 | 24.95 | 25.21 | 24.87 | 23.87 |
| Support 2 (S2) | 23.89 | 24.55 | 23.92 | 23.73 | |
| Support 3 (S3) | 23.10 | 23.89 | 23.58 | ||
| Support 4 (S4) | 23.16 |
